Ultragenyx (RARE)
Healthcare
Biotechnology
25.00 $
+0.4%
vs. previous close
Closing price · As of: 3. Aug 2026
Ultragenyx (RARE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -197 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -116 | -118 | -84 | -191 | -77 | -67 | -80 | -166 | -108 | -91 | -100 | -197 | -497 | |
| 5.4 | 7.2 | 8.2 | 8.8 | 8.9 | 8.8 | 9.1 | 9.0 | -12 | 8.6 | 8.8 | 8.0 | 14 | |
| 35 | 35 | 34 | 37 | 39 | 42 | 40 | 40 | 39 | 37 | 37 | 30 | 143 | |
| 7.2 | 2.8 | 15 | -56 | 16 | 31 | 23 | -57 | -22 | 55 | 0.6 | -51 | -17 | |
| 16 | 3.7 | 1.6 | 13 | 4.5 | 1.6 | 0.7 | 16 | 13 | 1.3 | 0.9 | 1.0 | 16 | |
| 99 | 64 | -107 | 94 | 61 | -276 | 103 | 120 | 71 | 117 | -72 | -49 | 67 | |
| – | – | – | -0.1 | 0.1 | – | – | – | – | – | – | – | – | |
| 33 | 25 | 331 | -0.1 | 385 | 11 | 3.2 | 0.2 | 84 | 0.0 | 394 | – | – | |
| 16 | -29 | 141 | -97 | 368 | -330 | 24 | -45 | 49 | 26 | 222 | -251 | 46 | |
| -133 | -122 | -86 | -204 | -81 | -69 | -80 | -183 | -96 | -93 | -101 | -198 | -487 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.